Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 3/20 | 0.43 |
| ▸ | FNTB | P49356 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18324786 | 0.86 | ALDH1A1 (0.42) | KCNH2FNTAFNTBALDH1A1TP53 | |
| SCHEMBL18324877 | 0.85 | TP53 (0.39) | KCNH2FNTAFNTBALDH1A1TP53 | |
| SCHEMBL18324880 | 0.83 | KDM4E (0.47) | ALDH1A1IDO1 | |
| SCHEMBL18324883 | 0.82 | ALDH1A1 (0.42) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7350572 | 0.80 | KCNH2 (0.44) | KCNH2TP53MAPT | |
| SCHEMBL7876404 | 0.79 | KCNH2 (0.43) | KCNH2TP53MAPT | |
| SCHEMBL18324779 | 0.78 | TP53 (0.43) | ALDH1A1TP53 | |
| SCHEMBL19239951 | 0.75 | TNKS (0.47) | KCNH2POLB | |
| SCHEMBL2675756 | 0.70 | HTR1D (0.41) | KCNH2POLB | |
| SCHEMBL4963277 | 0.70 | TNKS (0.56) | KCNH2FNTAFNTBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367564-A1 | Pharmaceutical Compound | TDO2, IDO1, IDO2 | KCNH2 3149/4885L3MBTL1 2033/4885FNTA 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.